Glioblastoma Weak Spot Discovery

Researchers at The Ohio State University Comprehensive Cancer Center identified a protein named SET as a potential weak spot in glioblastoma, one of the deadliest and most treatment-resistant brain cancers. Published on February 20, 2026, in the journal Cancer Letters, the study reveals that glioblastoma cells use proteins including SET, ANP32A, and CIP2A to suppress an enzyme called PP2A, which normally regulates cancer cell growth, survival, and DNA damage repair. The research team, led by experts such as Arnab Chakravarti, demonstrated that suppressing SET or interfering with related proteins in preclinical laboratory and animal models prevented tumor development and increased the vulnerability of cancer cells to radiation and chemotherapy. By blocking these defensive proteins, researchers aim to restore PP2A activity and make standard treatments significantly more effective against glioblastoma recurrence. Although these findings establish a clear biological pathway for future drug development, the therapeutic strategy remains at a preliminary preclinical stage and has not yet been tested in human patients. Investigators are currently evaluating whether SET and related PP2A inhibitors can be targeted safely, while also noting that an FDA-approved antipsychotic medication known to increase PP2A activity provides a rationale for future clinical trials. Medical professionals and researchers should monitor clinical trial developments targeting the PP2A regulatory pathway to assess future combination therapies for glioblastoma. Patients and practitioners are advised that existing drugs influencing this pathway are not yet approved for brain cancer treatment outside of formal clinical trials.